Brinks’ Biotechnology and Pharmaceutical practice group has more than 45 experienced attorneys and patent agents who are deeply versed in the complex and ever-evolving areas of the law specific to these industries, including specialized areas such as the Hatch-Waxman Act. Not only do we have in-depth industry knowledge and expertise gained through extensive service to our clients, but we also possess significant in-house counsel experience.
Being able to see and appreciate both sides to our client’s IP issues sets us apart from our competitors in the marketplace.
The pace of innovation in biotechnology and pharmaceuticals is unprecedented. Investments are costly, the stakes are high, and strong intellectual property rights are essential.
Developing the key relationships and understanding important objectives enables us to effectively anticipate our client’s needs in real-time scenarios.
Employing a comprehensive, multi-dimensional approach to delivering top-notch legal services allows us to remain both effective and cost-efficient for clients, remaining sensitive to their business goals and their bottom line.
This is how we help our clients. This is our way forward.